Faustino García-Candel
Faustino García-Candel is an expert in Hematology at Hospital Universitario Virgen de la Arrixaca (Spain). Faustino García-Candel has authored 29 publications, the most recent in 2025, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 90 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties:
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2014 - 2025
Number : 29
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Real-World Evidence on Joint Condition in Non-Severe Hemophilia A Patients: A Multicenter Study. PMID 40417706 — genes, thrombin, hemophilia a | J Blood Med | 2025 | 0 |
| TRAP-Induced Platelet Reactivity Is Inhibited by Omega-3 Fatty Acid-Derived Prostaglandin E3 (PGE3). PMID 39767761 — fatty acids, omega-3, thrombin, prostaglandins, platelet aggregation, blood platelets, fatty acids | Biomedicines | 2024 | 0 |
| ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy. PMID 38237147 — registries, purpura, thrombotic thrombocytopenic, hematology, recycling, diagnosis, therapeutics, blood platelets, purpura, thrombocytopenic | Blood | 2024 | 7 |
| N-Acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study. PMID 37171598 — purpura, thrombotic thrombocytopenic, hematology, acetylcysteine, purpura, thrombocytopenic, purpura, hematologic diseases | Ann Hematol | 2023 | 2 |
| Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura. PMID 35930694 — purpura, thrombocytopenic, hematologic diseases, immunosuppression therapy, hospitalization, therapeutics, odds ratio, purpura, thrombotic thrombocytopenic | Blood Adv | 2022 | 40 |
Clinical Studies 2
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| The Long term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial NCT06568302 — injections, hemophilia b, safety, hemophilia a, genes, apc, protein c | Phase 3 | Recruiting | 2024 |
LeadR Networks
Main global connection map